Parmax Pharma Ltd - 540359 - Outcome Of Board Meeting And Results For Quarter And Financial Year Ended 31St March, 2021.
Outcome of Board Meeting and Results for Quarter and Financial year ended 31st March, 2021.29-06-2021
29-06-2021
Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/06/2021 ,inter alia, to consider and approve Pursuant to Regulation 29(1) and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to notify that a meeting of the Board of Directors of the Company is proposed to be held on Tuesday, the 29th June, 2021 at 4:00 P.M. to, inter-alia, consider, approve and take on the record the Audited Financial Results for the quarter and year ended 31st March, 2021.23-06-2021
Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201505-06-2021
Parmax Pharma Ltd - 540359 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayParmax Pharma Ltd 2CINL24231GJ1994PLC023504 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 42668101.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: YASH VORA Designation: COMPANY SECRETARY EmailId: cs@parmaxpharma.com Name of the Chief Financial Officer: KEYUR VORA Designation: CHIEF FINANCIAL OFFICER EmailId: info@parmaxpharma.com Date: 01/05/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.01-05-2021
Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March, 2021.28-04-2021
Parmax Pharma Ltd - 540359 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half-Year Ended 31St March, 2021.
Certificate pursuant to Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half-year ended 31st March, 2021.25-04-2021
Parmax Pharma Ltd - 540359 - Shareholding for the Period Ended March 31, 2021
Parmax Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here19-04-2021
Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Demise
Intimation of sad demise of Shri Alkeshbhai R. Gosalia, Managing Director15-04-2021
Parmax Pharma Ltd - 540359 - Compliance Certificate Pursuant To Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 For The Year Ended On 31St March, 2021.
Compliance Certificate pursuant to Regulation 7(3) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 for the year ended on 31st March, 2021.05-04-2021
Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- YASH VORADesignation :- Company Secretary and Compliance Officer02-04-2021